Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Neurotrophic Factors and Depression

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-12-22
Last Posted Date
2008-12-22
Lead Sponsor
University of California, San Francisco
Target Recruit Count
30
Registration Number
NCT00812994
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

UCSF, San Francisco, California, United States

Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder

First Posted Date
2008-12-17
Last Posted Date
2011-06-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
840
Registration Number
NCT00810069
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Vigo, Spain

🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sisli, Turkey

Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-11-05
Last Posted Date
2010-01-13
Lead Sponsor
Community Pharmacology Services Ltd
Target Recruit Count
60
Registration Number
NCT00785434
Locations
🇬🇧

CPS Research, Glasgow, United Kingdom

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-10-07
Last Posted Date
2011-07-25
Lead Sponsor
Samsung Medical Center
Target Recruit Count
46
Registration Number
NCT00767871
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Treatment Response of Geriatric Depression

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-09-18
Last Posted Date
2019-03-19
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
106
Registration Number
NCT00754936
Locations
🇺🇸

Weill Cornell Medical College-Westchester Division, White Plains, New York, United States

Sinusitis and Facial Pain Disorders Anti-Depression Trial

First Posted Date
2008-09-18
Last Posted Date
2014-01-17
Lead Sponsor
University of Washington
Target Recruit Count
3
Registration Number
NCT00754793
Locations
🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

fMRI Studies of Emotional Brain Circuitry in People With Major Depression

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-09-09
Last Posted Date
2018-07-17
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
99
Registration Number
NCT00749125

Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-08-15
Last Posted Date
2010-03-23
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
38
Registration Number
NCT00736021
Locations
🇮🇱

Hadassah University Hospital, Jerusalem, Israel

Clinical Neurobiology of Serotonin and Addiction

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-08-12
Last Posted Date
2019-03-08
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
160
Registration Number
NCT00732901
Locations
🇺🇸

University of Texas Health Science Center-Houston; Substance Abuse Research Clinic, Houston, Texas, United States

Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-07-28
Last Posted Date
2011-08-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
176
Registration Number
NCT00723060
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath